Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective
Egle Ramelyte, Aizhan Tastanova, Zsolt Balázs, et al.
Cancer Cell (2021) Vol. 39, Iss. 3, pp. 394-406.e4
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Macrophages in immunoregulation and therapeutics
Shanze Chen, Abdullah F. U. H. Saeed, Quan Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 792
Clinical relevance of tumour-associated macrophages
Mikaël J. Pittet, Olivier Michielin, Denis Migliorini
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 402-421
Closed Access | Times Cited: 474
Therapy with oncolytic viruses: progress and challenges
Sophia Z. Shalhout, David M. Miller, Kevin S. Emerick, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 3, pp. 160-177
Closed Access | Times Cited: 290
Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 206
Type I interferon-mediated tumor immunity and its role in immunotherapy
Renren Yu, Bo Zhu, Degao Chen
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 3
Open Access | Times Cited: 195
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Yaomei Tian, Daoyuan Xie, Yang Li
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 171
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
Jason Chesney, Antoni Ribas, Georgina V. Long, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 3, pp. 528-540
Open Access | Times Cited: 153
Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell
Lu Diao, Mi Liu
Advanced Science (2023) Vol. 10, Iss. 22
Open Access | Times Cited: 70
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
Roger Li, Paras Shah, Tyler F. Stewart, et al.
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2216-2223
Closed Access | Times Cited: 19
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)
Julia Maria Ressler, Maud Plaschka, Rita Silmbrod, et al.
Nature Cancer (2025)
Open Access | Times Cited: 2
Magnetic‐Powered Janus Cell Robots Loaded with Oncolytic Adenovirus for Active and Targeted Virotherapy of Bladder Cancer
Zhaoqing Cong, Songsong Tang, Leiming Xie, et al.
Advanced Materials (2022) Vol. 34, Iss. 26
Open Access | Times Cited: 68
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
Zhi Zhu, A. J. Robert McGray, Weijian Jiang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 61
Nano based-oncolytic viruses for cancer therapy
Mobarakeh Ajam-Hosseini, Fatemeh Akhoondi, Mohammad Doroudian
Critical Reviews in Oncology/Hematology (2023) Vol. 185, pp. 103980-103980
Closed Access | Times Cited: 28
OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment
Shiyu Liu, Fan Li, Qiongqiong Ma, et al.
Theranostics (2023) Vol. 13, Iss. 12, pp. 4016-4029
Open Access | Times Cited: 25
Systemic Treatment of Melanoma
Reinhard Dummer, Simone M. Goldinger
(2024), pp. 1-15
Closed Access | Times Cited: 10
Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study
Yalei Zhang, Ling Qian, Kun Chen, et al.
Molecular Therapy (2024) Vol. 32, Iss. 6, pp. 2000-2020
Open Access | Times Cited: 9
m1A inhibition fuels oncolytic virus-elicited antitumor immunity via downregulating MYC/PD-L1 signaling
Shu‐Jin Li, Feng Tian, Yuan‐Tong Liu, et al.
International Journal of Oral Science (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 9
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects
Ada Donà, Theophilus Tandoh, Lokesh Nigam, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
Single-cell analysis of oncolytic virotherapy in adult T-cell leukemia/lymphoma
J. An, Erqiang Hu, Yang Shi, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e011265-e011265
Open Access | Times Cited: 1
Oncolytic Virotherapy: From Bench to Bedside
Ludi Yang, Xiang Gu, Jie Yu, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 43
Janus Micro/Nanorobots in Biomedical Applications
Haiyang Su, Shunxiang Li, Guang‐Zhong Yang, et al.
Advanced Healthcare Materials (2022) Vol. 12, Iss. 16
Closed Access | Times Cited: 36
Cancer gene therapy goes viral: viral vector platforms come of age
Urban Bezeljak
Radiology and Oncology (2022) Vol. 56, Iss. 1, pp. 1-13
Open Access | Times Cited: 34
Immunomodulatory effect of locoregional therapy in the tumor microenvironment
Lin Xie, Zhiqiang Meng
Molecular Therapy (2023) Vol. 31, Iss. 4, pp. 951-969
Open Access | Times Cited: 19
An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application
Dan Su, Han Li-ping, Chengyu Shi, et al.
Virulence (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Current landscape and perspective of oncolytic viruses and their combination therapies
Yinghan Su, Changqing Su, Lun‐Xiu Qin
Translational Oncology (2022) Vol. 25, pp. 101530-101530
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top